Top biotech an­a­lyst projects a gloomy out­look for Pfiz­er's JAK port­fo­lio

Many in the phar­ma world are hop­ing — bet­ter yet, ex­pect­ing — JAK in­hibitors to pro­vide one of the next big boons for the in­dus­try. Few have in­vest­ed as heav­i­ly in this area as Pfiz­er, which boasts a port­fo­lio in­clud­ing Xel­janz and at least five mid-to-late stage can­di­dates in the pipeline.

But a top Wall Street an­a­lyst is pump­ing the brakes on just how much good for­tune is in store for the Big Phar­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.